The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Role of immunotherapy in gastrointestinal stromal tumors
Michael C. Heinrich, MD, OHSU Knight Cancer Institute, Portland, OR, explores the use of immunotherapy in patients with gastrointestinal stromal tumors (GISTs), touching on strategies to increase the immunogenicity of the tumor microenvironment in order to improve the number of prolonged responses. Dr Heinrich also outlines the impact of tyrosine kinase inhibitors on responses to immune checkpoint blockade as evaluated in in vivo models. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
